Eslie Dennis MD

Dr. Eslie Dennis is Director of Clinical Biomarkers at the Critical Path Institute. She has 10 years of experience in clinical practice in internal medicine and hematology and laboratory research in the area of tuberculosis, and a further 14 years of experience in the pharmaceutical industry where she has held a variety of positions on medical and commercial teams. Dr. Dennis was most recently Vice President and Medical Head Northeast for Novartis Pharmaceuticals Corporation, where she led a field based medical affairs team and developed customer-focused and patient-focused medical strategies in partnership with key stakeholders. She has extensive experience overseeing pre-marketing development programs and leading post-marketing programs including Phase IIIb/IV, epidemiology and health economics and outcomes research. She created and led the Novartis Office of Grants and Education, and spearheaded the design, development, and implementation of best-in-class automated grants processing website. She has given substantial presentations (local, national, and international) to a wide range of groups and agencies on subjects ranging from access to medicines, key compliance risks regarding clinical trials, clinical relevance in trial design and product specific presentations. Dr. Dennis has been involved in activities such as regulatory negotiations with the FDA, training and development, strategic and budget planning, safety risk management and global market research. Dr. Dennis was also a Medical Advisor with Merck, Sharp & Dohme in South Africa, working with a small core group to establish medical affairs, support an expanding business and interact with South Africa's Ministry of Health. Dr. Dennis received her MBChB from the Godfrey Huggins School of Medicine in Harare, Zimbabwe, and was the recipient of the Winston Churchill, Margaret Low, and Prankard-Jones Scholarships, as well as the Guy Elliot Bursary. She is a Fellow of the College of Physicians of South Africa.


This speaker has made no appearances.